MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium

BACKGROUND: MET amplification and MET exon 14 alterations (METex14) in lung cancers impart sensitivity to MET kinase inhibitors. Fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), and IHC, have been used to evaluate MET dependency. Here, we determined the association of MET...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Thorac Oncol
Egile Nagusiak: Guo, Robin, Berry, Lynne D., Aisner, Dara L., Sheren, Jamie, Boyle, Theresa, Bunn, Paul A., Johnson, Bruce E., Kwiatkowski, David J., Drilon, Alexander, Sholl, Lynette M., Kris, Mark G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6708730/
https://ncbi.nlm.nih.gov/pubmed/31228623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.06.009
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak